Price movement over the last 24 hours
Abbott Laboratories vs Duolingo Inc — how do they compare? Abbott Laboratories trades at $95.31 (market cap $166.94B), while Duolingo Inc trades at $127.65 (market cap $6.15B). The key difference: Abbott Laboratories is far larger — about 27.1× Duolingo Inc's market cap, and Abbott Laboratories pays a 2.63% dividend while Duolingo Inc pays none. Which is the better fit depends on your goals.
| ABT | DUOL | |
|---|---|---|
Market Cap | $166.94B | $6.15B |
Sector | Health | Technology |
52-Week High | $136.62 | $390.84 |
52-Week Low | $82.57 | $90.03 |
Enterprise Value | $193.69B | $4.99B |
Dividend Yield | 2.63% | — |
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Duolingo (DUOL) trades at $131.95, up 4.92% with strong technical momentum and bullish moving average signals. The company demonstrates exceptional fundamental strength with 2025 revenue reaching $1.04 billion and net income of $414 million, representing a 38.4% margin. Recent earnings beats and expanding profitability highlight operational excellence amid AI-driven product expansion into math and music learning.
Outlook remains positive with projected 2026 revenue growth to $1.1 billion, though the stock trades above analyst consensus target of $110.20. Key risks include competitive pressure in edtech and valuation concerns with P/E of 14.8 and P/S of 5.7. Institutional sentiment leans cautious with 59% hold ratings despite strong fundamentals.
Trailing returns across standard periods
Latest headlines on both assets
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →Duolingo Inc is a mobile learning platform to learn languages and the top-grossing app in the Education category on both Google Play and the Apple App Store. It has three predominant sources of revenue
Read more on DUOL →